NCBiotech News

We work hard to bring you the stories about the life science community in North Carolina. Every once in a while, we add a little news of our own. Read some of those stories below, or check out some of our perspectives on our staff blog.

Chimerix logo
Durham-based Chimerix priced the stock offering late Wednesday, selling more than 11.7 million shares for $8.50 apiece to raise $100 million that can help bring lead drugs to FDA approval.
Target RWE logo
Target RWE, a clinical data company based in Durham, has acquired a neighboring software analysis and services company, NoviSci, and scored an investment from California biotech pioneer Amgen.
Grifols Johnston County facility
Global biotherapeutics giant Grifols will soon start a clinical trial for what could become the second approved treatment for COVID-19.
Shannon Boye with young patient
Atsena Therapeutics is a Durham clinical-stage gene therapy company with $63M in the bank so far to propel its mission to reverse and prevent blindness.
BTEC scene
A Jan. 28 virtual symposium, “BioGrow: Training and Education Across North Carolina,” is planned to get the word out to anyone interested in a career in biopharmaceuticals.
Adverum logo
California gene therapy innovator Adverum Biotechnologies announced plans today to invest some $83 million to establish a manufacturing site in Durham that will employ 202 people through 2026.
Diana De Leon
Diana De Leon, an 18-year-old recent Pitt County high school grad, is proof that satisfying, rewarding, career-worthy jobs are waiting for a wide range of North Carolinians in the field of pharmaceutical manufacturing. She's now employed at Thermo Fisher Scientific in Greenville.
Ribometrix small molecule
Ribometrix, a Durham company specializing in RNA-based therapeutics, has formed a drug discovery and development collaboration with Genentech that could be worth more than $1 billion.
Maurius logo
Raleigh-based Marius Pharmaceuticals, led by several former GlaxoSmithKline scientists and executives, is making progress on its first potential drug.
Centene building rendering
Business Facilities logo

Business Facilities magazine, a national publication serving corporate site selectors and economic development professionals, today proclaimed North Carolina the "2020 State of the Year."  

BioCryst logo
Durham's BioCryst Pharmaceuticals is developing its drug galidesivir as a potential treatment for more than 20 RNA viruses. SARS-CoV-2, the virus that causes COVID-19, will no longer be one of them.
Atox Bio logo
Atox Bio, an Israeli company with U.S. headquarters in Durham, has received FDA acceptance of its new drug application for reltecimod, a drug developed for patients with necrotizing soft-tissue infections.
Merz building exterior
Xeomin, a botulinum toxin therapy developed by Raleigh-based Merz Therapeutics, has gained yet another new use.
Taysha logo
Dallas-based Taysha Gene Therapies announced plans today to invest $75 million in a gene therapy manufacturing facility in Durham that will employ 201 people over the next three years.
Heat Biologics logo
Morrisville immunotherapies developer Heat Biologics is moving closer to human testing of a vaccine for COVID-19.